4-氰基-4-联苯羧酸 | 5728-46-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氰基-4-联苯羧酸
• 中文别名: 4-(4-氰基苯基)苯甲酸；4`-氰基-联苯-4-羧酸
• 英文名称: 4'-cyano-[1,1'-biphenyl]-4-carboxylic acid
• 英文别名: 4'-Cyan-biphenyl-4-carbonsaeure；4'-cyanobiphenyl-4-carboxylic acid；4-(4-cyanophenyl)benzoic acid
• CAS: 5728-46-1
• 化学式: C₁₄H₉NO₂
• 分子量: 223.231
• InChiKey: KBNUZLPQQMVGPR-UHFFFAOYSA-N

物化性质

• 熔点：
  263-266°C
• 沸点：
  443.0±38.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  61.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2926909090
• 危险性防范说明：
  P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(4-Cyanophenyl)benzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(4-Cyanophenyl)benzoic acid
CAS number: 5728-46-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H9NO2
Molecular weight: 223.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氰基-4-联苯羧酸 在 氯化亚砜 作用下， 反应 1.0h， 生成 4'-cyano-<1,1'-biphenyl>-4-carboxylic acid chloride
  参考文献：
  名称：

  Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs

  摘要：

  Anthranilamides 4 and 5 were designed and synthesized as selective and orally bioavailable factor Xa inhibitors. Structural modifications aimed at lowering their lipophilicity were performed at the central phenyl ring and at the S4 binding biphenyl region by incorporating water solublizing substituents. The resulting compounds (e.g., 7, 8, 14, 30a, and 32b) are highly potent in vitro, and show improved activity in human plasma-based thrombin generation assay. (C) 2004 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2003.11.079
• 作为产物：
  描述：

  4-氰基-[1,1-联苯]-4-羧酸甲酯 在 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 以80%的产率得到4-氰基-4-联苯羧酸
  参考文献：
  名称：

  组蛋白甲基转移酶SET7小分子抑制剂的发现，化学优化和生物学评估研究

  摘要：

  组蛋白的翻译后修饰，包括组蛋白甲基化和去甲基化，控制着多个基因的表达开关。包含SET结构域的赖氨酸甲基转移酶7（SET7）是唯一的甲基转移酶，它可以使组蛋白H3（H3K4me1）的赖氨酸4特异性单甲基化，并在多种疾病（包括乳腺癌，丙型肝炎病毒（HCV），动脉粥样硬化性血管疾病）中发挥关键作用，糖尿病，前列腺癌，肝细胞癌和肥胖症。但是，几种已知的SET7抑制剂表现出弱活性或差的选择性。因此，迫切需要开发新型的SET7抑制剂并具有很大的临床价值。在这项研究中，我们确定了2-79通过基于结构的虚拟筛选和进一步的基于AlphaLISA的生化评估作为一种新型命中化合物。通过化学优化，确认合成的化合物DC21为有效的SET7抑制剂，IC 50值为15.93μM。DC21和SET7之间的相互作用也通过SPR实验进行了验证。特别地，DC21在细胞水平上抑制了MCF7细胞的增殖，IC 50值为25.84μM

  DOI：

  10.1016/j.bmcl.2020.127061

文献信息

• [EN] HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES<br/>[FR] AGENTS RECEPTEURS DE L'HISTAMINE H3, PREPARATION ET UTILISATIONS THERAPEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2005097740A1

  公开（公告）日：2005-10-20

  The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases

  本发明公开了具有组合物(I)或其药学上可接受的盐的新颖化合物，其具有组胺H3受体拮抗剂或逆激动剂活性，以及制备这种化合物的方法。在另一实施例中，本发明公开了包含组合物(I)的药物组合物，以及使用它们治疗肥胖、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。
• HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
  申请人：Beavers Lisa Selsam

  公开号：US20100048580A1

  公开（公告）日：2010-02-25

  The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases

  本发明公开了化合物(I)的新颖化合物或其药学上可接受的盐，其具有组胺H3受体拮抗剂或逆激动剂活性，以及制备这种化合物的方法。在另一实施方案中，本发明公开了包含化合物(I)的药物组合物，以及使用它们治疗肥胖、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。
• Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives
  作者：Liyu Zhao、Wenbo Yin、Yin Sun、Nannan Sun、Linfeng Tian、Yang Zheng、Chu Zhang、Shizhen Zhao、Xin Su、Dongmei Zhao、Maosheng Cheng

  DOI：10.1016/j.ejmech.2021.113715

  日期：2021.11

  l-amino alcohol derivatives exhibited high antifungal activity, but the metabolic stability of human liver microsomes in vitro was poor, and the half-life of optimal compound 5 was less than 5 min. To improve the metabolic properties of the compounds, the scaffold hopping strategy was adopted and a series of antifungal compounds with a dihydrooxazole scaffold was designed and synthesized. Compounds

  l-氨基醇衍生物具有较高的抗真菌活性，但人肝微粒体体外代谢稳定性较差，最佳化合物5的半衰期小于5 min。为改善化合物的代谢特性，采用支架跳跃策略，设计合成了一系列具有二氢恶唑支架的抗真菌化合物。二氢恶唑环上被4-苯基取代的化合物A33-A38对白色念珠菌、热带念珠菌和克氏念珠菌表现出优异的抗真菌活性，MIC值在0.03~0.25  μ之间。克/毫升。此外，化合物A33和A34在体外人肝微粒体中的代谢稳定性显着提高，半衰期分别大于145 min和59.1 min。此外，SD大鼠的药代动力学研究表明，A33具有良好的药代动力学特性，生物利用度为77.69%，半衰期（静脉给药）为9.35 h，表明A33值得进一步研究。
• Amide Derivatives of 3-Phenyl-Dihydropyrimido[4,5-D]Pyrimidinones, Their Manufacture and Use as Pharmaceutical Agents
  申请人：Engh Richard

  公开号：US20070232611A1

  公开（公告）日：2007-10-04

  The present invention relates to novel amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, to a process for their manufacture, medicaments containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents. The present derivatives are new compounds of the general formula (I).

  本发明涉及3-苯基二氢嘧啶并[4,5-d]嘧啶酮的新酰胺衍生物，以及其制备方法、含有它们的药物、以及这些化合物作为药用活性剂的用途。本发明的衍生物是一般式(I)的新化合物。
• 4′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-carboxylic acid: Synthetic approaches, single crystal X-ray structures and antimicrobial activity of intermediates
  作者：Rodinel Ardeleanu、Andrei Dascălu、Sergiu Shova、Alina Nicolescu、Irina Roşca、Bogdan-Ionel Bratanovici、Vasile Lozan、Gheorghe Roman

  DOI：10.1016/j.molstruc.2018.06.086

  日期：2018.12

  ester function. The second synthetic pathway starts from 4-bromobenzonitrile, which is converted through Suzuki coupling with 4-carboxyphenylboronic acid into 4′-cyano-[1,1′-biphenyl]-4-carboxylic acid, which in turn leads to the desired compound after ring closure of tetrazole. All of the synthesized compounds have been fully characterized by IR and 1H- and 13C-NMR spectroscopy. Single crystal X-ray structures

  摘要 报道了 4'-(2H-四唑-5-基)-[1,1'-联苯]-4-羧酸的两种合成方法，4'-(2H-四唑-5-基)-[1,1'-联苯]-4-羧酸是一种用于制备金属-有机骨架的有价值的有机配体。产生目标化合物的第一个反应序列包括[1,1'-联苯]-4-羧酸的碘化，4'-碘-[1,1'-联苯]-4-羧酸甲酯的形成酸、碘与氰基的亲核取代、四唑的闭环和酯官能团的水解。第二条合成途径从 4-溴苯甲腈开始，通过 Suzuki 与 4-羧基苯基硼酸的偶联转化为 4'-氰基-[1,1'-联苯]-4-羧酸，然后再生成所需的化合物四唑的闭环。所有合成的化合物都已通过 IR 和 1H-和 13C-NMR 光谱进行了充分表征。报告了目标化合物和 4'-碘-[1,1'-联苯]-4-羧酸和 4'-氰基-[1,1'-联苯]-的甲酯的单晶 X 射线结构4-羧酸。目标化合物和中间体对大肠杆菌、金黄色葡萄球菌和白色念珠菌没有抗菌活性。